adult patients, 18-70 years of age

hepatitis c, genotype 1 or 4, of over 6 months duration

treatment-naïve

negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin

pregnant or breast feeding females or male partners of pregnant females

previous interferon or ribavirin based therapy or investigational anti-hcv agent

systemic antiviral therapy with established or perceived activity against hcv </=3 months prior to first dose of study drug

hepatitis a or b, or hiv infection

history or evidence of medical condition associated with chronic liver disease other than hcv